Biocryst
Navenibart
STAR-0215 / Hereditary angioedema / Phase 3 / Hereditary angioedema prophylaxis
Pipeline Watchlist
Company Pipelines
Recent additions
14 daysbiocryst.com
Bioatla
BA3362
Oncology
Bioatla
BA3241
Oncology / Preclinical / Solid tumors
Bioatla
BA3311
Oncology / Preclinical / Solid tumors
Bioatla
BA3142
Oncology / Preclinical / Solid tumors
Bioatla
BA3151
Oncology / Preclinical / Breast cancer
Axsome
AXS-20
CNS / Phase 3-enabling / Schizophrenia
Autolus
AUTO4
Oncology / Phase 1 / PTCL
Autolus
obe-cel
obecabtagene autoleucel / Oncology; Autoimmune disease / Phase 1 / B-NHL
Aura Biosciences
belzupacap sarotalocan
AU-011 / oncology / Phase 3 / early choroidal melanoma (small choroidal melanoma and/or indeterminate lesions)
Ataibeckley
Novel 5-HT2A Receptor Agonists
Mental health / In development / Opioid Use Disorder
Ascendis Pharma
TransCon CNP + TransCon hGH
navapegritide + lonapegsomatropin / Endocrinology rare diseases / Phase 2 / Achondroplasia (children aged 2-11)
Companies
ATAIAtaibeckley
4assets
Ataibeckley
- BPL-003BPL-003 / serotonergic neuromodulator / intranasal mebufotenin benzoate / Mental healthTreatment-Resistant DepressionPhase 2
- VLS-01VLS-01 / 5-HT1/2/6/7 sub-receptors / buccal film DMT / Mental healthTreatment-Resistant DepressionPhase 2
- EMP-01EMP-01 / oral R-MDMA / Mental healthSocial Anxiety DisorderPhase 2
- Novel 5-HT2A Receptor Agonists5-HT2A receptor / non-hallucinogenic neuroplastogens / Mental healthOpioid Use DisorderIn developmentTreatment-Resistant DepressionIn development